European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. Other key influences helping the upstream bioprocessing market expand include drug development, antibody manufacturing, as well as a higher need for cell therapy research. Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Process Improvement 98

Process Improvement Biosimilars Drug Development 98

FDA Law Blog: Biosimilars

OCTOBER 13, 2024

It is extremely difficult, if not impossible, to do the long-term planning and substantial fundraising required for drug development without knowing whether such an important and valuable incentive will be there. We heard and felt the anxiety from many of our clients about the uncertainty this caused.

Documentation 64

Documentation Drug Development 64

FDA Law Blog: Biosimilars

DECEMBER 23, 2024

Earlier in the week, it was reported that there was a bipartisan agreement on a bill that would have funded the government and extended the first sunset date for the rare pediatric disease priority review voucher program for nearly 5 years, until September 30, 2029.

Drug Development 59

Drug Development 59